Bowling Portfolio Management LLC acquired a new stake in Haemonetics Co. (NYSE:HAE) during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 11,413 shares of the medical instruments supplier's stock, valued at approximately $1,024,000.
Other large investors have also recently made changes to their positions in the company. Arjuna Capital purchased a new position in shares of Haemonetics in the 2nd quarter valued at $224,000. Wagner Bowman Management Corp purchased a new position in shares of Haemonetics in the 2nd quarter valued at $224,000. Zeke Capital Advisors LLC purchased a new position in shares of Haemonetics in the 2nd quarter valued at $244,000. Commonwealth Equity Services LLC purchased a new position in shares of Haemonetics in the 2nd quarter valued at $249,000. Finally, LS Investment Advisors LLC grew its position in shares of Haemonetics by 75.8% in the 2nd quarter. LS Investment Advisors LLC now owns 3,174 shares of the medical instruments supplier's stock valued at $285,000 after buying an additional 1,369 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors. Get Haemonetics alerts:
A number of research analysts recently commented on HAE shares. Zacks Investment Research raised shares of Haemonetics from a "sell" rating to a "hold" rating in a research report on Friday, May 4th. Morgan Stanley increased their target price on shares of Haemonetics from $77.00 to $100.00 and gave the company an "overweight" rating in a research report on Wednesday, May 9th. Jefferies Financial Group increased their target price on shares of Haemonetics to $95.00 and gave the company a "buy" rating in a research report on Wednesday, May 9th. Barrington Research increased their target price on shares of Haemonetics to $90.00 and gave the company an "outperform" rating in a research report on Wednesday, May 9th. Finally, TheStreet raised shares of Haemonetics from a "c+" rating to a "b" rating in a research report on Tuesday, May 8th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Haemonetics has a consensus rating of "Buy" and an average target price of $98.33.
NYSE HAE opened at $103.32 on Friday. The firm has a market capitalization of $5.16 billion, a P/E ratio of 55.25, a P/E/G ratio of 4.38 and a beta of 0.99. The company has a current ratio of 2.84, a quick ratio of 1.94 and a debt-to-equity ratio of 0.49. Haemonetics Co. has a 12 month low of $41.10 and a 12 month high of $108.37.
Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Tuesday, August 7th. The medical instruments supplier reported $0.59 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.42 by $0.17. The firm had revenue of $229.35 million during the quarter, compared to analysts' expectations of $219.52 million. Haemonetics had a net margin of 2.45% and a return on equity of 15.00%. research analysts forecast that Haemonetics Co. will post 2.28 EPS for the current fiscal year.
In related news, VP Dan Goldstein sold 3,794 shares of the stock in a transaction on Thursday, June 7th. The shares were sold at an average price of $95.09, for a total transaction of $360,771.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link . Also, CEO Christopher Simon sold 3,595 shares of the stock in a transaction on Friday, June 29th. The stock was sold at an average price of $40.39, for a total transaction of $145,202.05. The disclosure for this sale can be found here . In the last quarter, insiders have sold 23,711 shares of company stock valued at $1,926,700. 1.04% of the stock is owned by company insiders.
Haemonetics Company Profile
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. Haemonetics Haemonetic